Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Conditions
Interventions
None listed
Sponsors
Leiden University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: Patients are eligible for participation if they meet the following criteria: - They are diagnosed with a glioma, PCNSL, meningioma, or intracranial brain metastases; - They are adult patients: >=18 years of age; - They have signed the informed consent form. Proxies are eligible for participation if they meet the following criteria: - They are adults: >=18 years of age; - They are spouse, family member, or close friend of the patient; - They have signed the informed consent form. HCPs are eligible for participation if they meet the following criteria: - They work as neurologist, neurosurgeon, medical oncologist, radiation oncologist, neuropsychologist or specialist nurse in neuro-oncology; - They have at least 2 years of experience with primary brain tumours (glioma, PCNSL or meningioma) and/or metastatic (intracranial) brain tumours OR; - They treat patients with primary brain tumours (glioma, PCNSL or meningioma) and/or metastatic (intracranial) brain tumours in their daily practice (at least 20 per year).
Exclusion criteria
Exclusion criteria: Patients are not considered eligible for study participation if: - They are not eligible for participating in the study according to the treating physician, due to very poor physical condition or unable to provide consent to research participation (i.e. filling in the survey); - They cannot complete the survey due to a language barrier or limited understanding of the survey. Proxies are not considered eligible for study participation if: - They cannot complete the survey due to a language barrier or limited understanding of the survey.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this study is to establish the content validity of the available PRO measures used in primary and secondary brain tumour patients. Content coverage of the identified PRO measures will be defined as the percentage of items considered relevant (based on the survey results, see the statistical analysis for the determination of relevance). In addition, the percentage of relevant items that are not covered by the PRO measure will be defined and considered. Timepoint: This will be a prospective cross-sectional study. The study-specific survey will be sent one time to a convenience sample of brain tumour patients with a glioma, primary central nervous system lymphoma (PCNSL), meningioma or intracranial brain metastases and their proxies (informal caregivers) attending an outpatient clinic | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline characteristics of participating patients, including age, gender, level of education, relationship status, living arrangements, employment status, Karnofsky Performance Score (KPS), date of diagnosis, disease status, and current and previous anti-tumour treatments.Timepoint: This being a cross-sectional study, only the base-line characteristics will be analysed which will be collected at a given point of time only once during the course of the study | — |
Countries
Belgium, India, Netherlands, Switzerland, United Kingdom, United States of America
Contacts
Public ContactRakesh Jalali
Apollo Proton Cancer Centre
Outcome results
None listed